The discovery of the effect of cyclooxygenase-2 (COX-2) inhibitors, such as celecoxib (Fig. 2) or meloxicam [83] in many types of malignancies, especially in breast cancer [84-86], made 1,5-diphenylpyrazoles became important structures to work with. This evidence concerns the gene PTGS2 and breast carcinoma.